[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368951-105":59,"doc-detail-368951-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genomics-of-uterine-malignancies-and-the-potential-of-precision-medicine","Genomics of uterine malignancies and the potential of precision medicine","","Uterine malignancies form a broad, heterogeneous set of neoplasms that account for most gynaecological cancers in developed countries. For many patients, high mortality and poor clinical outcomes stem from complex molecular profiles and aggressive phenotypes that resist standard therapies. Precision medicine and targeted treatment advances are transforming several common cancers, yet comparable benefits remain limited across uterine cancer subtypes. This review surveys molecular features defining these subtypes and evaluates therapeutic strategies targeting them.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomics-of-uterine-malignancies-and-the-potential-of-precision-medicine/368951/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomics-of-uterine-malignancies-and-the-potential-of-precision-medicine/368951.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are uterine malignancies difficult to treat with conventional therapies?","Question",{"text":112,"@type":113},"Many cases show complex molecular profiles and aggressive phenotypes that are largely refractory to conventional approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the review cover regarding uterine malignancy subtypes?",{"text":117,"@type":113},"It details diverse molecular features characterising multiple uterine malignancy subtypes and reviews therapeutic approaches targeting those features.",{"name":119,"@type":110,"acceptedAnswer":120},"Which targeted strategies does the review highlight as promising?",{"text":121,"@type":113},"It highlights HER2-targeted therapies for HER2-positive malignancies, TP53 wild-type targeting with selinexor, and approaches involving AKT and DNA repair pathway inhibitors, alongside antiangiogenic and immune checkpoint inhibitor combinations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368951,1790270054,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Genomics of uterine malignancies and the potential of precision medicine  \nJoseph Polidano, Andrew Jarratt, Clare L. Scott and Holly E. Barker  \nAbstract: Uterine malignancies represent a broad and heterogeneous group of neoplasms, which collectively account for the majority of gynaecological malignancies in developed countries. For a significant proportion of these, mortality rates and clinical outcomes are of major concern, owing to complex molecular profiles and aggressive phenotypes that are largely refractory to conventional therapeutic approaches. Recent advancements in precision medicine and the development of targeted therapies have been transformative for several common cancer types; however, the same benefits are yet to be realised for many uterine cancers. This review comprehensively details the diverse molecular features characterising the various subtypes of uterine malignancies. Furthermore, we have examined the therapeutic approaches actively investigated to target these unique molecular features, identifying pathways and treatments that offer the greatest potential patient benefit.  \nAmong increasingly personalised strategies, particular promise is shown by HER2-targeted therapies for HER2-positive malignancies (e. g. trastuzumab deruxtecan) . Additionally, targeting TP53 wild-type tumours with selinexor, as well as addressing AKT and DNA repair pathways in both uterine carcinomas and sarcomas (i. e. AKT inhibitor and poly(ADP-ribose) polymerase inhibitor combinations), represents key advancements. Furthermore, antiangiogenic and immune checkpoint inhibitor combinations hold significant promise for future therapeutic strategies.  \nPlain language summary  \nInvestigating the potential of matching drugs to specific molecular changes in uterine cancers  \nUterine malignancies represent a common and complex group of cancers affecting many individuals. Unfortunately, a significant proportion of these are very aggressive and challenging to treat with standard methods. Recent progress in matching treatments based on DNA and molecular changes in individual malignancies have been transformative for several common cancer types, however the same benefits are yet tobe shown for many uterine malignancies. In this review, we explore new treatments that are currently being studied to specifically target these genetic and molecular features, highlighting the personalised approaches that show the most promise for patients.  \nKeywords: clinical trials, molecular testing, molecular therapeutics, precision oncology, targeted therapy, uterine cancer  \nReceived: 3 November 2024; revised manuscript accepted: 25 September 2025.  \nTherAdv Med Oncol 2025, Vol. 17: 1–28  \nDOI: 10. 1177/  \n17588359251387395 © The Author(s), 2025. Article reuse guidelines:  \n[sagepub.com/journals](sagepub.com/journals)permissions  \nCorrespondence to:  \nHolly E. Barker  \nCancer Biology and Stem Cells Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia  \n[barker.h@wehi.edu.au](barker.h@wehi.edu.au)  \nJoseph Polidano Andrew Jarratt  \nWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia  \nDepartment of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia  \nClare L. Scott  \nWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia  \nDepartment of Obstetricsand Gynaecology, The University of Melbourne, Melbourne, VIC, Australia  \nThe Royal Women’s Hospital, Parkville, VIC, Australia  \nPeter MacCallum Cancer Centre, Melbourne, VIC, Australia  \n[journals.sagepub.com/home/tam](journals.sagepub.com/home/tam) 1  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  \n([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) wh","cbCaiv5QvhYobNyw","https://ap.wps.com/l/cbCaiv5QvhYobNyw","pdf",729826,28,"English","# Abstract\n## Molecular features and precision oncology\n## Targeted therapeutic approaches\n## Plain language summary\n## Background of uterine malignancies\n## Pathological subtypes and incidence\n## Survival rates","[{\"question\":\"Why are uterine malignancies difficult to treat with conventional therapies?\",\"answer\":\"Many cases show complex molecular profiles and aggressive phenotypes that are largely refractory to conventional approaches.\"},{\"question\":\"What does the review cover regarding uterine malignancy subtypes?\",\"answer\":\"It details diverse molecular features characterising multiple uterine malignancy subtypes and reviews therapeutic approaches targeting those features.\"},{\"question\":\"Which targeted strategies does the review highlight as promising?\",\"answer\":\"It highlights HER2-targeted therapies for HER2-positive malignancies, TP53 wild-type targeting with selinexor, and approaches involving AKT and DNA repair pathway inhibitors, alongside antiangiogenic and immune checkpoint inhibitor combinations.\"}]","Genomics of uterine malignancies and the potential of precision medicine | PDF",1790179723,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbd16ee46dd7003bf3f3a868229186f0.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/334f51684018a5d1c503d850c258945d.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c0bfea67895d82f25bf8f54119e75c1.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7c78bcead1855ec78f49b34cce8a9ff.webp",980,1306]